Roche to buy U.S. biotech group Adheron Therapeutics

ZURICH, Oct 9 (Reuters) - Swiss drugmaker Roche will acquire U.S. biotech group Adheron Therapeutics in a deal worth up to $580 million that boosts its pipeline of products to treat diseases such as rheumatoid arthritis, Adheron said on Friday.

California-based Adheron’s technology disrupts immune cell adhesion through a protein called Cadherin-11. Its lead asset, SDP051, is a humanised monoclonal antibody that has completed Phase 1 of clinical development.

Read Full Article Here:

Recent Posts

See All

Contact Us | Disclaimer Privacy Policy | Partners Innovation

© Copyright Partners Innovation Fund